Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
Open Access
- 27 November 2023
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 11 (1) , 1-13
Abstract
In IDH-mutant astrocytoma, IDH2 mutation is quite rare and biological mechanisms underlying tumor progression in IDH2-mutant astrocytoma remain elusive. Here, we report a unique case of IDH2 mutant astrocytoma, CNS WHO grade 3 that developed tumor progression. We performed a comprehensive genomic and epigenomic analysis for primary and recurrent tumors and found that both tumors harbored recurrent IDH2R172K and TP53R248W mutation with CDKN2A/B hemizygous deletion. We also found amplifications of CDK4 and MDM2 with PDGFRA gain in the recurrent tumor and upregulated protein expressions of these genes. We further developed, for the first time, a xenograft mouse model of IDH2R172K and TP53R248W mutant astrocytoma from the recurrent tumor, but not from the primary tumor. Consistent with parent recurrent tumor cells, amplifications of CDK4 and MDM2 and PDGFRA gain were found, while CDKN2A/B was identified as homozygous deletion in the xenografts, qualifying for integrated diagnosis of astrocytoma, IDH2-mutant, CNS WHO grade 4. Cell viability assay found that CDK4/6 inhibitor and PDGFR inhibitor potently decreased cell viability in recurrent tumor cells, as compared to primary tumor cells. These findings suggest that gene alterations that activate retinoblastoma (RB) signaling pathways and PDGFR may drive tumor progression and xenograft formation in IDH2-mutant astrocytoma, which is equivalent to progressive IDH1-mutant astrocytoma. Also, our findings suggest that these genomic alterations may represent therapeutic targets in IDH2-mutant astrocytoma.Keywords
Funding Information
- Japan Society for the Promotion of Science (22K09210, 19K09488)
This publication has 50 references indexed in Scilit:
- A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survivalGenes & Development, 2013
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in GliomasJournal of Clinical Oncology, 2009
- Human Glioblastoma–Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus VectorsCancer Research, 2009
- IDH1andIDH2Mutations in GliomasNew England Journal of Medicine, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- INK4a/ARF: A multifunctional tumor suppressor locusMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005
- A role for platelet-derived growth factor in normal gliogenesis in the central nervous systemCell, 1988